the development of therapies and vaccines for human hepatropic pathogens requires robust model systems that enable the study of host-pathogen interactions. However, in vitro liver models of infection typically use either hepatoma cell lines that exhibit aberrant physiology or primary human hepatocytes in culture conditions in which they rapidly lose their hepatic phenotype. to achieve stable and robust in vitro primary human hepatocyte models, we developed micropatterned cocultures (Mpccs), which consist of primary human hepatocytes organized into 2D islands that are surrounded by supportive fibroblast cells. By using this system, which can be established over a period of days, and maintained over multiple weeks, we demonstrate how to recapitulate in vitro hepatic life cycles for the hepatitis B and c viruses and the Plasmodium pathogens P. falciparum and P. vivax. the Mpcc platform can be used to uncover aspects of host-pathogen interactions, and it has the potential to be used for drug and vaccine development. 
IntroDuctIon
Liver pathogens collectively mount an enormous global burden on human health; hepatitis B virus (HBV) chronically infects the livers of >250 million people worldwide, hepatitis C virus (HCV) chronically infects the livers of 130-170 million more, and the Plasmodium protozoan underlying malaria matures asymptomatically within the liver before causing cyclic fever in the blood stages during its infection of over 250 million individuals globally. These two viruses exhibit very distinct genome structures and life cycles, yet HCV and HBV both use parenteral transmission, after which they establish chronic infection in the hepatocyte, the main parenchymal cell type of the liver. Chronic infection in a subset of patients leads to fibrosis and ultimately end-stage liver diseases such as cirrhosis and hepatocellular carcinoma 1, 2 . Malaria is transmitted by Plasmodium sporozoites after they are injected into a human host via a mosquito vector. These uninucleate sporozoites invade hepatocytes, where they establish exoerythrocytic forms (EEFs) that mature and multiply to form schizonts, which eventually release thousands of pathogenic merozoites into the blood. Merozoites invade erythrocytes and lead to the major clinical symptoms, signs and pathology of malaria. What is shared by all three of these pathogens is their exclusive dependence on the human hepatocyte host environment for a portion of their life cycles. The hepatocyte is a normally quiescent, polarized, specialized, species-specific cell type that is uniquely susceptible to infections. Capturing its phenotype ex vivo using engineering methods to manipulate its microenvironment has been beneficial for understanding human metabolism and toxicity. Here, we discuss the origins and evolution of our engineered MPCC microliver platform (Fig. 1) , in the context of other existing in vitro liver model systems.
We outline the specific requirements of an experimental platform suitable for the study of diverse pathogens, and we describe how the MPCC has been adapted to serve as an infection model for DNA and RNA viruses, as well as for acute and relapsing parasitic infections.
There have been considerable strides made in the clinical management of hepatotropic pathogens in recent years. For example, a safe and effective HBV vaccine exists, and yet incomplete immunization of at-risk individuals allows disease burden to grow, and current antivirals for HBV do not typically cure chronically infected patients. Furthermore, although direct-acting HCV antivirals have emerged with marked cure rates across a variety of genotypes, prophylactic options for HCV remain unavailable 3 . For malaria, drug resistance is emerging, only a few drugs target liver-stage parasites, and only one licensed drug eliminates the dormant hypnozoite form of P. vivax, which causes clinical relapses [4] [5] [6] . Collectively, there are strong motivations for the development of improved vaccines and therapeutic interventions. Achieving a more complete understanding of the biology of HBV, HCV and the Plasmodium pathogens, and their pathogenesis within human hosts, will drive improvements in the clinic. However, because of the narrow species tropism of HBV and HCV, the only robust animal model is the chimpanzee, which is costly and often inaccessible. Notably, forward progress is being made in the development of liver-humanized mouse models of hepatitis B, hepatitis C and malaria, yet-to date-these tools are still generally restricted to a small number of research laboratories 7, 8 , and their reproducibility and reliability need to be further demonstrated. As such, the majority of research programs tackling these diseases typically use in vitro models of the liver 9 . Conventional in vitro liver models Over the past two decades, a variety of in vitro liver models have been developed and used in the study of basic hepatocyte function and metabolism, in addition to their application in establishing platforms for investigating hepatropic infections. Some examples of these models include whole organs, wedge biopsies, liver slices, microsomes, cell lines and primary hepatocytes (either in suspension or in adherent culture) [10] [11] [12] [13] , several of which use confluent hepatocyte monolayers and extracellular matrix (ECM) manipulations (such as collagen and Matrigel) 11, 14, 15 . However, as with most in vitro models, each system is subject to a range of limitations with respect to the faithful recapitulation of human liver biology, as described below.
Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens
Whole livers, liver slices and biopsies. Whole livers, biopsies and slices retain in vivo cytoarchitecture and liver-specific hepatocytestromal interactions, yet they have restricted viability (usually <48 h, although some reports demonstrate limited hepatic functions for up to 10 d (ref. 16 )), they require complex logistics to work with successfully and they do not allow medium-to highthroughput screening (HTS) because of donor organ shortages. Microsomes are used in HTS to identify enzymes involved in drug metabolism but lack the gene expression and cellular machinery required for investigating complex cellular responses. There have been some advances in culture of liver slices in microfluidic devices to prolong their lifetime 17 ; even this short-term extension of viability (<72 h) still precludes the possibility of prolonged drug dosing over several weeks. Furthermore, each experiment using slices is, by necessity, from a different liver donor, which can make data difficult to interpret across experiments because of donor-to-donor variability in responses. Slices also do not allow investigators to create culture platforms on-demand from the 'bottom-up' using cryopreserved cells from the same donor, which can be customized for specific applications and at the level of throughput required.
Cell lines. Hepatoma-derived cell lines and immortalized hepatocytes provide inexpensive and plentiful cell sources for experimentation, yet they are known to display abnormal liver-specific functions such as uncontrolled proliferation, dysregulated gene expression, altered host responses to infection, inadequate drug metabolism capacity, dysfunctional mitochondria and abnormal endocytic functions 18, 19 . The HepaRG hepatoma-derived cell line differentiates spontaneously into hepatocyte-like and cholangiocyte-like cells after several weeks of culture in vitro, and it displays higher liver functions relative Stem cell-derived hepatocytes. In spite of the improvement in several hepatic model systems, those discussed above all rely on nonrenewable sources (e.g., primary tissue availability). Cryopreservation has certainly enhanced the capacity for such work, yet renewable sources are still desirable for establishing large-scale, automation-compatible platforms and studies on isogenic backgrounds. To this end, advances in induced pluripotency and directed differentiation protocols have led Duncan and colleagues 32 and several other groups 33 to produce hepatocyte-like cells (iHLCs) from numerous genetic backgrounds; however, such cells do not yet exhibit a fully mature adult phenotype 33 , and the protocols have been proven to be challenging to miniaturize. Recent progress has been made to produce iHLCs in 96-well formats 34 , but these efforts still require normalization strategies to account for stochastic well-to-well variations in differentiation efficiencies. Nonetheless, similar to their primary human hepatocyte counterparts, micropatterning strategies can be used to further mature stem cell-derived human hepatocyte-like cells. Notably, Khetani, Berger, and colleagues adhered iHLCs onto collagen-coated domains optimized via micropatterning, surrounded these islands with 3T3-J2 mouse embryonic fibroblasts and then added a Matrigel overlay (i.e., they combined the MPCC platform with an ECM sandwich technique). In this context, the MPCC platform can further mature human iHLCs toward adult primary human hepatocytes and maintain functions for at least 4 weeks in vitro relative to conventional pure iHLC monolayers 35 . These so-called 'iMPCCs' produced high levels of albumin and urea, maintained major CYP450 and phase II drug metabolism enzyme activity, and were sensitive to effects of drugs (induction, toxicity) with in vivo-relevant trends. Moreover, the capacity for the MPCC assay to be populated with iPS-derived cells offers the potential to model rare genotypes, as well as access to an expandable cell population, although-despite improvements in hepatocyte-derivation protocols-iPS-derived hepatocyte-like cells remain an imperfect proxy for adult cells 33, 36 , and they often require substantial culture expertise. In a separate undertaking, we have identified small-molecule 'maturins' that promote the maturation of iHLCs toward a more adult phenotype 36 . Ongoing efforts seek to isolate the signaling pathways responsible for these outcomes, as well as to apply the small molecules in our 2D micropatterned platform, as well as 'on chip' in perfused 3D formats that link multiple lineages of iPS-derived cell types 37 .
Utility of in vitro hepatic model systems in the study of hepatropic pathogens
The establishment of this plethora of model human liver systems opened the door for their use in the study of hepatropic pathogens, particularly in the case of those that exclusively infect human hepatocytes. As discussed above, considerable work is also ongoing to improve existing liver-humanized mouse models, but thus far the application of these models to studies of pathogen infections has been limited to a narrow portion of the research community, and thus this section is focused on the utility of in vitro models in this context. The central design criteria for an ideal model of human hepatropic infections include the expression of entry receptors to permit initial infection, host factors that support replication and longevity to support the entire life cycle of the pathogen in question (days for HBV and HCV, and in the case of Plasmodium parasites, ~7-10 d for the acute phase and ~21 d for relapse). Successful support of the pathogen's life cycle is probably mediated in part by the stable maintenance of quiescent, polarized, differentiated hepatocytes that remain coupled by tight junctions. In addition, it is particularly desirable if the selected model system offers the capacity for miniaturization, as most human pathogens are difficult to source (for example, HBV, HCV, P. falciparum and P. vivax), and therefore test inoculum is typically a biomass limitation in the case of scaled experiments. To date, the in vitro study of hepatotropic pathogens most commonly uses cell lines.
The HCV community has typically relied on the Huh-7 and Huh-7.5 hepatoma cell lines, along with other subclones, to study infection. HBV work has relied upon the HepG2 hepatoblastoma cell line and variants containing integrated viral sequences, and DMSO-differentiated cultures of the hepatoma line HepaRG (ref. 38) . These lines may exhibit numerous morphologic and functional abnormalities, meaning that findings obtained using these models, especially those relating to host-virus interactions 39 , often deviate from those observed in vivo. Other laboratories have developed primary human hepatocyte models that permit hepatropic pathogen infection, notably the Guguen-Guillouzo group for HBV infection 40 , and, more recently, other groups have established models of HCV infection [41] [42] [43] . Nonetheless, it remains to be determined whether these models offer the stability in hepatic phenotype, reproducibility and robustness that is routinely observed with MPCCs.
As is the case with HBV and HCV, our current understanding of the liver stages of P. falciparum and P. vivax, the major species of human malaria parasites, is also based in large part on the infection of human hepatoma cell lines [44] [45] [46] [47] [48] . In addition to the drawbacks of cell lines discussed above, the observation of parasite or virus development in liver cell lines is challenging after 6 d in culture, as the infected cells continue to proliferate and detach from culture 49 . Notably, Mazier and colleagues have combined the sandwich culture method with the use of Matrigel and HepaRG cells, and it has been shown to be permissive to P. falciparum infection and can maintain Plasmodium cynomolgi infection for up to 40 d (ref. 50) . This prolonged culture period opens the door for the system to be suitable for P. vivax studies, and it offers a complementary platform for experiments aimed at achieving reactivation of hypnozoites. Nonetheless, given the abnormal, transformed nature of the HepaRG cells, the cultures established via this method may produce a random coculture of hepatocytes and cholangiocytes. This heterogeneous culture environment may well prove to be useful for certain malaria infection applications, yet it is also likely to be limited by experiment-to-experiment variability.
As early as 1984, the Mazier laboratory established the full life cycle of both liver forms of human malaria in cultured, primary human hepatocytes in two landmark studies 51, 52 . Mazier and her collaborators have continued to leverage access to fresh liver tissue, infected mosquitos and culture expertise to apply their platform to the study of P. falciparum and P. vivax [51] [52] [53] [54] . However, the use of primary hepatocyte systems by the broad liver-stage malaria community has been minimal, probably in part because of the difficulty in translating these cells into reproducible formats for screening, limited cell availability, as well as challenges in maintaining phenotypic function over extended periods in vitro 55 . Thus, for longitudinal studies of hepatotropic pathogens such as HBV, HCV and Plasmodium, the aforementioned models have offered limited progress in the field 56, 57 .
Development of the MPCC protocol
Given the drawbacks of the above models, we sought to develop an engineered system that builds on existing advances to create reliable, robust miniaturized primary systems that replicate the authentic host biology of the primary human hepatocyte. In this paper, we discuss the development and use of an in vitro culture technology called MPCC, which we have developed, optimized and applied to problems in human health over the past 10 years 28, [55] [56] [57] . This coculture system of primary human hepatocytes and 3T3-J2 mouse embryonic fibroblasts is robust, reproducible and miniaturized in a standard multiwell plate format compatible with automated workflow environments, and it sustains hepatocytes for 4-6 weeks in culture. Primary human hepatocytes can be sourced either fresh or cryopreserved from many human donors, and selected lots are then qualified for use in downstream applications. We have successfully used MPCCs to study the infection and drug response for HBV, HCV and malaria [56] [57] [58] . Our aim in sharing the historical derivation and our insight into the evolution of the MPCC is to provide a roadmap for the community to replicate, test, improve and hopefully adopt the model in order for it to expedite progress in achieving clinical impact for patients suffering from disease.
Before our foray into adapting in vitro models of human hepatocytes for the purposes of modeling liver infections, the original steps toward the development of MPCCs were inspired by early work focused on the role of physical homotypic (hepatocyte-hepatocyte) and heterotypic (hepatocyte-stromal) cell-cell interactions modulating hepatocyte functions in vitro. In particular, pioneering studies by Guillouzo and colleagues demonstrated transient induction of some functions in primary human hepatocytes cocultivated with an epithelial cell type, also derived from the liver 59 . However, in these early studies, the two cell types were randomly distributed onto planar surfaces, which did not allow exploration of the role of controlled cell-cell interactions on the hepatic phenotype without the confounding variable of cell seeding density. To circumvent this limitation, Toner and Bhatia adapted photolithography methods used by the semiconductor industry to physically position defined, 2D islands of primary rat hepatocytes on adsorbed collagen surrounded by supportive 3T3-J2 mouse embryonic fibroblasts 55 . Such micropatterning allowed tuning of the relative levels of homotypic and heterotypic interactions while keeping cell numbers and ratios between the two cell types constant across the various patterned configurations. The first iterations of these experiments revealed that defining various levels of homotypic cell-cell interactions alone had a crucial role in modulating hepatocyte functions by several fold. Functions of micropatterned hepatocyte colonies were then significantly augmented in both magnitude and longevity by contact coculture with stromal cells 55 . In particular, a functional screen revealed that the J2 subclone of 3T3 mouse embryonic fibroblasts (3T3-J2, isolated by Green and colleagues 60 ) induced optimal functions in hepatocytes from multiple species (rat, human) as compared with other available 3T3 clones (i.e., NIH-3T3, Swiss-3T3, L1-3T3) (ref. 61) . Given significant differences between animals and humans in liver functions [62] [63] [64] , the aforementioned micropatterning configurations were applied to freshly isolated primary human hepatocytes. We noted that although an interplay between the ratio of homotypic and heterotypic interactions was still needed to induce optimal functions in human hepatocytes cocultivated with 3T3-J2 fibroblasts, the optimal configuration was distinct from that required by their rat-derived liver counterparts 28 . Another notable advance was achieved by Khetani and Bhatia when we developed soft-lithographic techniques that allowed for rapid creation of MPCCs in miniaturized formats for higherthroughput screening than that afforded by the serial process of photolithography for direct seeding of cells 28 . Furthermore, MPCC-creation protocols were optimized by investigators at Hepregen Corporation (Medford, Massachusetts, USA) to leverage advances in the production of cryopreserved primary human hepatocytes by multiple vendors (e.g., Life Technologies, BioreclamationIVT). The use of cryopreserved hepatocytes affords several advantages, which include the following: convenient on-demand experimentation as opposed to the unpredictability in procurement of fresh cells; longitudinal studies in the same donor when required, as opposed to significant inter-experimental variability observed with the use of fresh hepatocytes from different donors; and comparisons across responses in multiple donors for specific downstream applications. All of the aforementioned advances have culminated in modern-day MPCCs, which have been optimized for human hepatocyte functions in industrystandard 24-and 96-well formats ( Figs. 1 and 2 ). Current 'best practice' cultures consist of 500-µm islands (~200 hepatocytes per island), spaced 700-1,200 µm apart center-to-center, with supportive mouse 3T3-J2 fibroblasts in the remaining spaces. Such architectures remain intact in both fidelity of patterning and hepatic morphology and functions for several weeks.
Applications of MPCC to hepatotropic infections
The earliest studies of MPCCs focused on the elucidation of basic mechanisms underlying hepatocyte-stromal cocultures and drug metabolism, as well as for preclinical evaluation of drug toxicity 28, 62, [65] [66] [67] [68] [69] . For instance, MPCCs have been shown to be ~70-75% predictive of clinical outcomes for drug metabolite and drug-induced liver toxicity profiling, as opposed to <50% sensitivity in standard culture systems 65 . These and other characterizations of the MPCCs led us to assay whether the platform would satisfy the requirements of an in vitro model of human hepatropic pathogens, including host factor expression and facility to adapt the protocol to permit infection and development of candidate pathogens (Fig. 3) . By collaborating with the Rice, Mota and Sanaria research groups, we have succeeded in applying MPCCs to study the life cycle of HCV 57 , HBV 58 and human Plasmodium 56, 70 pathogens. In one example, we performed head-to-head comparisons and found that other conventional primary human hepatocyte culture models-such as hepatocytes on rigid collagen, collagen gel sandwiches, Matrigel spheroids and even randomly distributed co-cultures of the same two cell types used in MPCCs-do not sustain HBV or HCV infection as robustly as MPCCs 57, 58 . On the basis of these successes, we have focused this report on the use of MPCCs with this collection of hepatropic infections (Figs. 4-6 ), but our findings suggest that our coculture platform can also be used to study hepatotropic pathogens broadly. Indeed, in our ongoing studies, we have confirmed that it is possible to achieve dengue virus infection of MPCCs, and although to date we have not used the platform to study infection with HAV and HEV (hepatitis A virus and hepatitis E virus, respectively) these are interesting areas for future study. After the demonstration that MPCCs support a pathogen's life cycle, a natural extension of this in vitro system is its use in candidate drug and vaccine screening to determine efficacy against the target pathogen. In this case, data derived from the study of these drugs in MPCCs are likely to be more representative of the human population when using primary human hepatocytes from multiple donors (Fig. 3 ) rather than single transformed donors. In addition, because of stable activities of drug metabolism enzymes (that is, cytochrome P450s) and drug transporters, MPCCs allow simultaneous evaluation of drug metabolism and/or toxicity, and the efficacy of candidate compounds in the same hepatocytes 57 . By virtue of their support of hepatropic pathogen life cycles, MPCCs can also be used for basic biological explorations of host-pathogen interactions that are not easily recapitulated in transformed and abnormal hepatic cell lines used in the field. As an example, we have recently used MPCCs to study the interplay between HBV/HCV/Plasmodium and the interferon axis present in hepatocytes, an inquiry that was previously challenging given the defective innate immune signaling exhibited by cell lines 58 . Another advantage of MPCCs is that hepatocytes exhibit polarized morphology over several weeks with appropriate localization of entry receptors and bile canaliculi, which in turn permit studies of cell-cell direct spread of HCV, for example ref. 28 . In addition, beyond rodents and humans, MPCCs have been established using hepatocytes from other species, including nonhuman primates 71, 72 . In some pathogens, such as Plasmodium, the human-tropic species can be challenging to source. One approach that has been taken in some laboratories is to evaluate the biology of another malaria species, P. cynomolgi, as a surrogate for P. vivax 50, 73 .
Liver research programs over the past few decades have been stymied by poor access to in vitro models with stable liver functional phenotype and appropriate polarization. Thus, beyond infection, MPCCs can also be used to study more broad questions of liver physiology and pathophysiology (e.g., cholesterol trafficking, carbohydrate regulation, production of serum components) 74 . Further, as exemplified by studying infection and other assessments of drug toxicity (e.g., acetaminophen) 66 , MPCCs allow the study of primary human hepatocytes under backgrounds of specific disease states. This capacity makes it likely that MPCCs will assist in studies of fatty liver, fibrosis, alpha-1 antitrypsin deficiency (particularly by collecting hepatocytes from genetic mutant backgrounds) and aspects of hepatocellular carcinoma.
Experimental design
MPCC infection experiments consist of three main phases: fabricating the model (Steps 1-31), characterizing the components (Steps 32-33) and using MPCCs to interrogate infection (Steps 34-35; Fig. 1 ).
Fabricating the model. As primary hepatocytes need adsorbed ECM (i.e., collagen) to adhere to culture surfaces, the first protocol stage details the precise culture specifications that achieve seeding of the cultures. MPCCs have been adapted successfully to both industry-standard 24-and 96-well plate formats, to suit varying experimental requirements; 96-well layouts are typically used when greater throughput is sought, such as screening drug candidates, or when some aspect of the infection protocol is limiting (e.g., novel drugs, pathogens). The other primary specification to consider is the selection of MPCC island diameter and spacing; these parameters can influence essential experimental criteria, such as hepatocyte function, infection efficiency and the total number of target cells available for infection. In addition,
we have recently found that the density of hepatocyte islands can also influence infection rates 70 . Once these culture specifications are determined, a mold using elastomeric polymers (usually polydimethylsiloxane (PDMS)) can be fabricated using standard photo-and soft-lithographic techniques 75 . The mold then serves as the reusable instrument with which to micropattern collagen simultaneously into each well of multiwell plates. Briefly, well plates are coated with collagen; a PDMS mold is then placed on the well plate to protect collagen-coated islands to which hepatocytes will selectively attach ( Fig. 1) . At this point, oxygen plasma gas is used to ablate collagen-coated surfaces that are not protected by the mask, leaving only the array of collagen islands in prespecified architecture. The micropatterned plates can immediately be used for cell seeding, or they can be refrigerated for a few months in a desiccator without noticeable loss of cell attachment capacity. Each well of the plate is seeded with primary human hepatocytes (from fresh or cryopreserved sources) and shaken three or four times per hour to ensure uniform seeding of hepatocytes onto all ECM islands in the well. Once the islands are >85% filled with hepatocytes over 3-5 h, the cells that have not adhered are removed by washing the wells with culture medium to prevent nonspecific attachment of hepatocytes to bare plastic areas because of adsorption of serum proteins from culture medium. Adhered hepatocytes are then allowed 18-24 h to fully spread onto the islands to make fully confluent clusters. Stromal cells (i.e., mouse 3T3-J2 fibroblasts) are seeded onto the hepatocyte cultures the following day in the presence of serum proteins that mediate their attachment to the intervening regions (Fig. 2) . If desired for the particular application, additional cell types can be seeded after this second stage. For example, Kupffer macrophages have been selected as an immune environment-modifying population; however, by themselves, these macrophages, liver sinusoidal endothelial cells 76 and other liver-derived stromal cell types do not stabilize hepatic functions, and thus the 3T3-J2 cells remain an important component of the current MPCC platform. The controlled nature of the cultures achieves reproducibility between batches, especially with the use of prequalified cryopreserved human hepatocyte lots, and it allows for the testing of hypotheses related to the impact of specific cell types.
Characterizing the components of the model. Biomarkers for characterizing MPCCs can be used to optimize selection of a candidate hepatocyte cell source (i.e., commercially available, numbered lots of cells from specific donors), to confirm that cultures are highly functional while maintaining longevity of functions for the time-period required and to subsequently assess the impact of pathogen infection and/or therapeutic intervention (Fig. 3) . Secretion of hepatocyte biosynthetic products (albumin, urea), CYP450 activity and morphology (including appropriate polarization with appearance of bile canaliculi) are biomarkers used at various time points during the culture life span. Typically, we screen a collection of hepatocyte lots from several human liver donors in parallel using the aforementioned biomarkers to select those donors that display stable phenotypic functions for several weeks in MPCCs. Cryopreserved hepatocyte lots that are sold under the label of 'plateable' by various vendors (i.e., BioreclamationIVT, Life Technologies, Triangle Research Labs) typically attach to collagen islands in MPCCs and display stable phenotype for 4-6 weeks in vitro. Hepatocytes from younger donors (<10 years of age) have been found to function for 6 weeks and longer in limited instances 28 .
Using MPCCs to interrogate infection.
MPCCs that successfully maintain longevity can be used for infection experiments. Such experiments can be tweaked as per the needs of the researcher.
The typical approach is to infect with the pathogen of interest and then use assays that are specific to that pathogen (Figs. 4-6 ). Below, we will discuss details of this process for HCV, HBV and Plasmodium infection. Assays can be used to monitor infection, for example, in the context of drug screening or other perturbations in basic biology studies.
Experimental controls. During the course of developing MPCCs as infection models for Plasmodium, HBV and HCV, several controls were performed to compare the rates of infection of MPCCs with randomly organized cocultures with the same cell types, as well as other culture models (e.g., cell lines, monolayer culture, sandwich culture). In a given MPCC experiment, to control for any unknown variables that are present in the assays that we use to quantify infection, it is advisable to include drug treatment controls in each experiment, in which known antiviral or antiparasite drugs are dosed during and after infection to provide a negative control.
Limitations
Compared with conventional seeding of a cell line on well plates, establishment of MPCCs is more involved when the process for patterning the plates and seeding of multiple cell types are taken into account. However, the ability to store collagen-patterned plates for several months at 4 °C decouples the batch patterning process in multiwell plates from the seeding of the cell types on two separate days. Regardless, the added effort to create MPCCs affords the researcher the ability to evaluate prolonged drug dosing regimens on stable primary hepatocytes, which otherwise may require time-consuming and far more challenging investigations in vivo.
In certain experimental contexts, the current MPCC format can present a problem in that it requires the use of mouse fibroblasts as the supportive cell type. For instance, mouse fibroblasts may represent a confounding detail in certain immunologic studies that require cells with an exclusively human background. In addition, any time a non-hepatocyte-specific biomarker is assessed in MPCCs, fibroblast-only controls typically need to be carried out to ascertain hepatocyte-specific responses. However, as the MPCCs are a 2D monolayer of cells, high-content imaging has been successfully used to determine the effects of perturbations on hepatocytes and fibroblasts, allowing assessment of both hepatocyte-specific and non-hepatocyte-specific effects in the same well, a key advantage of MPCCs 36, 68 . Ultimately, it would be ideal to replace the fibroblasts altogether with stromal cell-derived molecules that stabilize the hepatic phenotype. Considerable efforts are being made to achieve fibroblast replacement using defined microenvironment cues such as small molecules, proteoglycans, cadherins and biomaterials, yet the complete temporal and spatial combinatorial sequence of fibroblast-derived molecules has not yet been determined 36, 61, 77, 78 .
MPCCs are also currently limited by their finite life span, although these cultures do persist far longer than other hepatocyte systems (that is, hours to days versus 4-6 weeks). As such, infection experiments cannot be monitored over the course of many months (e.g., in the study of fibrosis related to HCV or HBV infection, or for the purposes of assaying for hypnozoite reactivation in long latency P. vivax strains). Currently, MPCCs are better suited for the study of initial infection and acute disease progression, whereas it is challenging to apply this model for the study of true 'chronic' HCV or HBV infection. We do see a decline in viral protein production coupled to maintenance of covalently closed circular DNA (cccDNA) level at time points 2 weeks after HBV infection 58 , which may be indicative of a switch from an acute to a chronic phase of infection, although there are other explanations for this phenomenon-such as innate immune stimulation limiting host and viral translation. Overall, the inability to maintain MPCC function indefinitely is likely to be due to some component of in vivo physiology (e.g., certain nonparenchymal cell types) and/or aspects of 3D architecture that are missing in vitro. Related to this limitation is the finding that, as in other in vitro systems used in the community, infection is not as robust in MPCCs as it is in vivo. Recent preliminary data suggest that innate immune signaling is relatively more active in the in vitro cultures than had been anticipated on the basis of in vivo findings, and this difference may contribute to the dampened HCV infection efficiency observed in this platform (data not shown). Nonetheless, as MPCCs are built 'bottom-up' from individual components, they can be used as a base platform on which to engineer additional liver-specific microenvironmental cues in order to better mimic liver physiology and disease states 13 .
With regard to Plasmodium parasite growth, the sizes reported in our system are similar to what has been previously observed in other in vitro systems at day 5 (refs. 51,73,79) , but they are smaller than those observed in vivo at day 5 (refs. 80,81) or in humanized mouse models 82 . It is possible that conformational cues may be important for parasite growth (for example, 2D versus 3D contexts), or that EEF size is affected by hepatocyte packing density. Notably, we recently reported that in vitro parasite growth can be increased in MPCCs by modulating the cell surface oxygen tension experienced by the hepatocytes 70 .
MaterIals

REAGENTS
Culturing fibroblasts
3T3-J2 fibroblasts (courtesy of H. Green, Harvard Medical School) 60 or NIH-3T3 fibroblasts (ATCC) 83 
Pathogen sources
Fresh or cryopreserved P. falciparum and P. vivax sporozoites (Sanaria) ! cautIon It is highly recommended that persons using this product ensure that they are fully trained in all aspects of safety related to the product. Generate HCV stocks for infection by electroporation of HCV RNA into Huh7.5.1 cells, followed by collection, purification and concentration of secreted infectious virions 85 (Box 1) ! cautIon It is highly recommended that persons using this product are fully trained on all aspects of safety related to the product, and that they adhere to Biosafety Level 2 or higher practices during the use of this product. De-identified HBV + human plasma (tested negative for HIV, HCV; Red Cross, see Box 2) or HBV from infected from HepG2.2.15 cells 86 (Box 3) ! cautIon Plasma derived from humans must be derived from sources that obtain patient consent. It is highly recommended that persons using this product are fully trained on all aspects of safety related to the product, and that they adhere to Biosafety Level 2 practices during use of this product. 14. At, or just before, 120 h after electroporation the cells should begin to look unhealthy and the collection should cease. 15. Clarify the supernatant by centrifugation at 1,000-2,000g for 5-10 min at RT. The stock can be concentrated using Millipore Amicon 100 kDa MWCO. Spin the sample at 1,000g until it has been concentrated to less than 1 ml. Refill the tube several times in order to concentrate the initial volume 25×. Divide the stock into cryovials. Slow-freeze the stock by placing it at −80 °C.  crItIcal step Long-term storage at 4 or −20 °C will result in decreased titer. 
Box 2 | Preparation and characterization of patient-derived HBV stocks
1. Obtain de-identified patient plasma (e.g., from the Red Cross) that is HBV + , and also negative for HCV and HIV.
Genotyping of the virus stocks • tIMInG 4h
2. Extract DNA from plasma. 3. Perform PCR using the following primers, using the conditions in Step 35J of the main PROCEDURE:
(F) 5′-CTCCACCAATCGGCAGTC-3′; (R) 5′-AGTCCAAGAGTCCTCTTATGTAAGACCTT-3′
4. Sequence the PCR products using the following primer: 5′-CCTCTGCCGATCCATACTGCGGAAC-3′ 5. Determine the genotype using the US National Center for Biotechnology Information (NCBI) online genotyping tool (http://www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi).
prepare viral stocks for infection • tIMInG 2-3 h 6. Incubate HBV + patient plasma with 25 mM CaCl 2 for 30 min at 37 °C. 7. Spin gelled plasma at 14,000g for 5 min at RT, and then remove the supernatant and transfer it to a new tube. 8. Repeat steps 6 and 7 until no visible clot remains at the end of the 5-min spin.  crItIcal step Ensure that no clot remains in the final viral stocks, or else clots may form over cells in culture upon infection.  pause poInt Viral stocks can be frozen down at −80 °C and stored for up to 12 months at this step, although a decrease in viral titer may occur. 9. Test the viral titer. Because HBV derived from the plasma of different patients can vary widely in the viral titer, it is important to test the supernatant from initial infectious inoculums for viral titer in each experiment. This is done by performing qPCR for viral DNA, as described in Step 35J. To maintain consistency across several experiments, it is also possible to pool viral stocks generated from plasma across many patients, and to freeze down aliquots at this step.
Box 3 | Preparation and characterization of HBV from infected HepG2.2.15 cells
As an alternative to using HBV + patient plasma, HBV virions can be produced and concentrated from the supernatant of HepG2.2.15 cells 96 . The advantage to using HepG2.2.15-derived viral stocks is that virions can be set to a standard titer beforehand, and they are additionally free of other plasma factors, antibodies to HBV and so on that may compromise infection or affect the health of the MPCCs. Our initial experiments used HBV + patient plasma because we were interested in infection with patient-derived virus, but this decision can be made on a case-by-case basis. Tissue culture flasks 44, 45, 89 . Extract sporozoites from infected mosquitoes by dissection of their salivary glands and by passing the glands back and forth through a 26G needle fitted to a 1-ml syringe.
Further purification and cryopreservation are optional 45, 90 .
• 
3|
Mix the PDMS base and curing agent at a 10:1 ratio, and place the mixture in a vacuum desiccator under vacuum to degas the PDMS mixture.
4|
Pour degassed PDMS into Teflon molds, making sure to fill in entirety the 'pillars' that extend into the well plates and to maintain a flat rectangular base of PDMS on top of pillars (this section needs to be at least ~2 mm thick to ensure flatness along the PDMS). 
6|
Carefully pull PDMS off the Teflon piece after casting, being sure to peel slowly to avoid tearing the PDMS. If large defects arise during this process, the PDMS should be recast and cured.  pause poInt PDMS is stable, and the cured bases can be stored at room temperature (RT; 20-25 °C) for years.
7|
Design and produce high-resolution transparencies containing the island patterns for MPCCs. Standard island sizes are circles with a 500-µm diameter, with 700-1,200 µm center-to-center spacing between islands.
8|
Order patterned silicon masters using standard foundry services (e.g., Trianja technologies, SimTech, FlowJem), ensuring that island regions are recessed in the master with a feature height of 150-250 µm.
9|
Upon receiving the silicon master, glue the wafer into a glass Petri dish of appropriate size by smearing a few drops of PDMS (10:1 base to curing agent) onto a Petri dish and then pressing the wafer onto these drops. Ensure a tight seal such that the wafer remains flat on the Petri dish surface (that is, by using a weight), and cure it overnight at 65 °C.
10|
Silanize the master by dropping a few drops of trichloro(1H,1H,2H,2H-perfluorooctyl)silane into a plastic weighing dish and suspending the master upside down, directly above this weighing dish in a vacuum desiccator for 2 h. Replace the trichloro(1H,1H,2H,2H-perfluorooctyl)silane and repeat the 2-h treatment.
11|
Slowly pour the degassed PDMS mixture (10:1 base to curing agent) over the silicon master until a uniform layer of PDMS coats the glass dish into which the master is glued. Degas PDMS in vacuum desiccator again after it is poured, and note the exact volume of PDMS used to fill the dish so that future casts are performed with the same volume. After degassing the mixture, cure PDMS overnight at 65 °C.
12|
Carefully cut the cured PDMS from the outside edge of the glass dish using a scalpel. Next, peel the cured PDMS layer off the silicon master by gently loosening the PDMS from the outside edge of the glass dish and then by slowly peeling the entire PDMS layer off. Be careful not to bend PDMS too far, or else PDMS may tear. The PDMS layer that was on top of the silicon master now has the negative replica of the features present on the master.
13|
Use metal punches (McMaster Carr) to core out individual 'buttons' (for each well of the multiwell plate) from the PDMS with the relevant features. In particular, use a 14-mm punch for a 24-well plate and a 6-mm punch for a 96-well plate format.
14|
Attach the PDMS buttons to the large PDMS base layer (cast on the Teflon molds) to create the final two-part PDMS etch mask. First, mix a 10:1 ratio of PDMS base to the curing agent, and add 1:1 vol/vol hexanes to this mixture to create 'PDMS glue.' Then, flip the PDMS base layer such that the pillars for each well are facing up, cover each pillar surface with PDMS glue using a spatula or brush and firmly place one cored-out PDMS button containing raised islands onto each pillar. Ensure that each button is firmly attached to the pillar below, and then cure the entire assembly overnight at 65 °C to complete fabrication of the PDMS etch mask. Place a weight (i.e., a flat glass surface with a metal weight on top) on the entire assembly to ensure that all the buttons glued onto the base structure are at the same height and leveled.  pause poInt The PDMS etch mask can be stored at RT indefinitely. Store it with clear tape covering the buttons.
preparation of micropatterning plates • tIMInG 2 h 15| Prepare 25-50 µg/ml collagen solution. Dilute stock collagen with ddH 2 O. PBS can be used; however, because it leaves a salt residue in each well, the number of washes (Step 18) needs to be increased to a total of five to remove the salt, which can affect patterning.
16|
Fill each well of a 24-or 96-well plate with 250-400 or 50-100 µl, respectively, of collagen solution. Up to 8-10 plates can be prepared at once with relative simplicity, although more can be made for large experiments.
17|
Incubate the plates for 60-120 min at RT or for 30-60 min at 37 °C.
18|
Rinse them three times with ddH 2 O.
19| Dry the plates thoroughly-bang the plates onto paper towels and let them dry in the back of culture hoods near the air vent for at least 2 h, although overnight drying is also acceptable.  pause poInt The plates can be stored for up to 3 months sealed in a plastic bag with desiccant pack at 4 °C.
20|
Clamp the etch mask to the plate. Tighten it such that the pattern is evenly visible on the bottom of the plate.  crItIcal step Do not overtighten; columns may bend, thus exposing those regions that are to be shielded from plasma ablation.
21|
Insert it into the plasma chamber and close it.
22| Expose it to 50-100 W oxygen plasma for 30-120 s (this may need to be optimized to obtain optimal protein patterning, depending on the plasma system used).
23|
Release the vacuum, open the plasma chamber and remove the device. Unclamp the mask from the plate.
24|
Sterilize the plate in a tissue culture hood under UV light for 15 min. If UV light is used, it is important to use an appropriate meter to ensure that the UV intensity in the bulb of the tissue culture hood has not diminished significantly. If UV is not available, wells can be incubated with 70% ethanol in ddH 2 O (300 µl per well) for 20 min followed by 3× rinses with sterile ddH 2 O.  pause poInt The plates can be stored for up to 3 months sealed in a plastic bag with a desiccant pack at 4 °C.
Handling of primary human hepatocytes 25|
If cryopreserved hepatocytes are used, follow option A; if fresh hepatocytes suspended in preservation buffer are used, follow option B.
(a) thawing of cryopreserved primary human hepatocytes • tIMInG 30 min  crItIcal step It is also important to execute Step 25A(iii-v) as quickly as possible (<1 min) to avoid injury to hepatocytes because of higher temperatures and the presence of concentrated cryoprotectant in the vial. Thus, thawing no more than one or two vials at once is recommended.
(i) If a cryopreserved vial is taken out of a liquid nitrogen dewar, loosen the cap very slightly (half a turn on a thread should be sufficient) to let any nitrogen gas out and prevent the vial from bursting open upon thawing in the next step. Then, tighten the cap before thawing. (ii) Thaw the vial in the water bath at 37 °C. Typically, 2 min is sufficient to thaw the vial such that a small ice crystal is still visible. However, the thawing time should be optimized depending on the volume in the vial and vendor instructions. (iii) Spray the vial with 70% (vol/vol) ethanol and wipe it clean quickly to ensure that the potentially contaminated water from the water bath is removed before Step 25A(v). (iv) While the vial is still tightly closed, invert it a few times in the tissue culture hood to mix the contents, as hepatocytes often settle to the bottom of the vial. (v) Uncap the vial in the tissue culture hood and immediately add the contents of the vial on top of 40 ml of prewarmed (in 37 °C water bath for 15-30 min) culture medium (DMEM with 1% (vol/vol) penicillin-streptomycin without serum) in a 50-ml conical tube.  crItIcal step It is important not to use serum in the medium in order to achieve specific patterning on collagen islands in subsequent steps without nonspecific attachment to the plastic regions because of adsorption of serum proteins. Step 25A(ix) to obtain a cell suspension of known cell density for seeding. • tIMInG 2 d (2-4 h active time) 26| Plate the cells in each well. For a 24-well plate, seed 250,000 hepatocytes in a final volume of 300 µl per well; for a 96-well plate, seed 70,000 hepatocytes in a final volume of 70 µl per well. These seeding densities can be optimized depending on the attachment efficiency of the hepatocyte lot. We have used as low as 150,000 hepatocytes and 30,000 hepatocytes in 24-and 96-well formats, respectively.
seeding cells in ecM micropatterned plates
27|
Put the cultures in the incubator. Then, three or four times each hour, take the plate out of the incubator and shake it three times by hand in both the horizontal and then the vertical perpendicular planar axes (not circular) to homogenize the cells in each well, as hepatocytes settle to the edges of the wells given their size distribution. The cells start seeding onto the islands in 15-20 min, and they should be visible from the bottom of the plate macroscopically under appropriate lighting.  crItIcal step The plate should be out of the incubator for no more than 30 s each time. In addition, ensure that shaking is not done so vigorously so as to splash the cell suspension out of the well and into the space between wells.
28| Every 2 h after seeding, inspect island-filling density under the microscope. When 85-90% of the islands are covered with hepatocytes, typically after 2-4 h, proceed to the next step.
29| Rinse unattached cells away by gentle aspiration from each well. Next, rinse 2-3 times with culture medium (DMEM with 1% vol/vol penicillin-streptomycin without serum) in immediate succession until a clear pattern is observed and minimal cells are observed under the microscope between the hepatocytes islands.  crItIcal step Approximately 1-5% of the cells will still be in suspension in each well even after the washings. These cells typically do not attach well onto the plastic, and they are washed away the next day upon fibroblast seeding.
30| 24 h after seeding hepatocytes, remove the medium from each well with gentle aspiration, and seed 3T3-J2 mouse embryonic fibroblasts in hepatocyte culture medium. Use 40,000 total cells in a volume of 300-400 µl volume per well of a 24-well plate and 7,000 total cells in 50-70 µl per well of a 96-well plate.
31|
Culture the plates, which can now be described as MPCCs, for 4-6 weeks or until desired for infection and/or analysis. Collect the supernatant from MPCCs every 24-48 h, and replace it with fresh hepatocyte medium. Supernatant samples can be stored at −20 or −80 °C until further use, typically for up to 12 months at −80 °C.
Hepatocyte selection and evaluation (functional assays and infectibility)
• tIMInG multiple 30 min-3 h assay points over 3 weeks 32| As a first step toward qualifying candidate hepatocyte donor lots for use in long-term infection experiments (e.g., HCV persistence and Plasmodium vivax hypnozoite biology), keep MPCC cultures for at least 3 weeks and perform the observations described in each of the following options (Fig. 3) . For option A, perform microscopic observations every 2-4 d. For option B, assess human albumin and urea secretion at the end of the 3-week period.  crItIcal step Screen 5-10 hepatocyte lots from distinct donors for suitability in each application, and bank 1-3 qualified lots for continued and on-demand use in infection studies. (ii) Assay the levels of human albumin and urea secretion using appropriate kits (specific kits that can be used for this purpose are listed in the reagents section). (iii) Select a hepatocyte lot to use for malaria, HBV or HCV infection that exhibits stable (within 25%) albumin secretion and urea production for at least 3 weeks in culture (Fig. 3) .  crItIcal step Stable albumin secretion and urea production are required to enable prolonged infection and drug-dosing studies. The levels of these markers can vary across human hepatocyte donors. Typical ranges are provided in our publications 13, 15 .
33| Maintain hepatocytes that show both suitable morphological traits and consistent human albumin and urea secretion over a period of at least 3 weeks. Functional maintenance of a particular lot of hepatocytes is necessary but not sufficient to ensure infectibility by either malaria parasites, HBV or HCV. As such, it is recommended that hepatocyte lots that pass the functional screening described above be further assayed for their capacity to support infection by either pathogen (Step 34A-C; Fig. 3 ).
Infection of Mpccs with hepatotropic pathogens
 crItIcal If the analysis method planned requires microscopic analysis, ensure that MPCC cultures are established on glass-bottomed 96-well plates or 12-mm glass coverslips in the wells of a plastic 24-well plate. Use 50 or 300 µl of medium per well of a 96-or 24-well plate, respectively. For some analysis methods, the procedure will need to be modified while performing the following steps; check this before starting this section.
34|
Infection conditions have been optimized for each pathogen. If you are infecting MPCCs with Plasmodium sporozoites, follow
Step 34A. If you are infecting them with HCV or HBV, follow
Step 34B or C, respectively (Fig. 3c) (ii) Remove the culture medium and add the suspension of sporozoites to the relevant wells of the plate. Shake the plates in a perpendicular axis within the same plane, two times in each direction. (iii) Centrifuge the plate at 600g for 5 min at RT. (iv) Incubate the infected plates at 37 °C and 5% CO 2 for 3 h. (v) After 3 h, wash the wells three times with hepatocyte culture medium (50 and 300 µl per well of a 96-or 24-well plate, respectively). (vi) Seed 3T3-J2 mouse embryonic fibroblasts in hepatocyte culture medium, as described in Step 30. Replace the medium 24 h after the fibroblast seeding and subsequently daily.  crItIcal step If nonaseptic mosquitoes are used, increase the concentration of penicillin-streptomycin to 3% during and after the 3-h infection period. Supplement the hepatocyte medium with amphotericin B, which is also called Fungizone (1:1,000), only after the 3-h infection period-i.e., with the addition of the 3T3-J2 fibroblasts. (iv) Inoculate the cells with HCV JFH-1-based stocks (typically final concentration TCID 50 per ml >10 6 as titered on permissive Huh-7.5 hepatoma cells is ideal, diluted in hepatocyte medium). Infection is typically done by incubating MPCCs with virus for 24 h. ! cautIon Materials in contact with HCV should be decontaminated after use according to the appropriate safety protocols followed in your research environment.  crItIcal step It is also possible to infect cells with HCV before 3T3-J2 seeding, as described for malaria in
Step 34A. However, we typically infect soon after fibroblast seeding. Waiting to infect for too long post fibroblast seeding typically reduces subsequent infection rates. ! cautIon Materials in contact with HBV should be decontaminated after use according to the appropriate safety protocols followed in your research environment.  crItIcal step It is possible to infect cells with HBV before or after 3T3-J2 seeding; however, we typically infect soon after fibroblast seeding. Infection can be performed up to at least 5 d after 3T3-J2 seeding, depending on the application, although infection rates may decrease. We recommend infecting 48 h after hepatocyte seeding. 
Infection analysis 35|
Perform infection analysis, by following the appropriate method(s) for each pathogen. If MPCCs are infected with Plasmodium sporozoites, follow option A for a sporozoite gliding assay, option B for a cell membrane wounding and repair assay, option C for a double-staining assay for sporozoite entry and option D for immunofluorescence staining of Plasmodium-infected MPCCs. If MPCCs are infected with HCV, follow option E for a Gaussia luciferase-HCV assay, option F for a viral (NS5B) polymerase inhibitor usage assay and option G for a viral production assay. Because HBV has a complex life cycle, it can be important to measure several markers of viral persistence and replication. If MPCCs are infected with HBV, the HBsAg ELISA (option G) and HBeAg ELISA (option H), each reflect measures of viral protein production, with HBeAg being detected reliably only in high-level infection. Viral 3.5-kb RNA, which represents both the pregenomic RNA and the longest viral mRNA coding for the core protein, is used as a measure of viral transcription, and its quantification is covered in option I. Viral DNA can be quantified both intracellularly and from the supernatant (option J), and it is a measure of virion production; cccDNA is the long-lived genomic form of HBV that is considered a hallmark of true, productive infection (option K). Information about when to use particular assays is given at the start of each option.
(a) sporozoite gliding assay • tIMInG 4 h  crItIcal step Both fresh and cryopreserved Plasmodium sporozoites may demonstrate significant batch-to-batch variability in gliding motility 56 . Therefore, it may be helpful to quantify the percentage of gliding sporozoites as an indicator of sporozoite 
antIcIpateD results
After seeding the hepatocytes on the micropatterned surfaces and establishing a coculture with the fibroblasts, the functional hepatocyte phenotype can be maintained for up to 4-6 weeks. Levels of infection with malaria, HBV or HCV vary across pathogen and hepatocyte donors, and to date no direct correlation has been established with respect to the levels of hepatocyte function or expression of host factors that forecast the extent of Plasmodium sporozoite or hepatitis infection. That is, these factors have been shown to be necessary but not sufficient for infection (data not shown). MPCCs remain susceptible to Plasmodium or HCV infection for many weeks after the patterning process; however, infection rates are optimal at day 1 or day 2 after seeding for Plasmodium, and at day 5 for HCV.
For malaria
If high-quality fresh sporozoites are used to infect MPCCs at 1-2 d after seeding, an infection rate between 0.5 and 1.5% can be expected at day 3 after infection. If MPCCs are infected at later time points, the infection rate at day 3 after infection decreases at different rates, depending mainly on the hepatocyte donor and secondarily on the motility of the sporozoite batch. If cryopreserved sporozoites are used, a reduction of ~7-10 fold is expected. The difference between the number of EEFs observed at day 3.5 versus the number at day 5.5 is defined as the 'progression rate', and this metric varies between hepatocyte donors. At day 3.5, EEFs in MPCCs exhibit an average size of 5 µm in diameter and a granular appearance (Fig. 4) . These two features allow for users to easily differentiate mature EEFs from undeveloped or axenic EEFs (those that initiate development extracellularly but that do not progress), and they are important measures to collect in order to avoid false positives. At days 5 and 7 after infection, MPCCs infected with P. falciparum parasites can range in size, in part because of differences in sporozoite quality and/or the hepatocyte donor cells used, but they typically exhibit an average size of 10-15 µm and 15-20 µm, respectively, and they are similar in size to those that have been previously reported in other in vitro systems at day 5 (refs. 51,73,79) . However, larger EEFs have been observed in vivo at day 5 (30-50 µm) 80, 81 or in humanized mouse models (18-22 µm at day 5 and 54-69 µm at day 7) (ref. 82) . Nonetheless, we consistently observe that P. falciparum EEFs continue to grow in MPCCs for at least 7 d after infection 56 .
Infection of MPCCs with P. vivax leads to the presence of big forms (schizonts) with an average of 25 µm on day 8, and small forms (<10 µm) that persist as long as the MPCCs are maintained 56 . The sizes of the MPCC-derived schizonts are similar to those that have been previously reported in vitro 52 . By using cryopreserved P. vivax sporozoites, the infection efficiency, based on the percentage of hepatocytes containing large and small PvCSP + EEF forms at day 6 after infection, is ~0.013% and 2%, respectively. These numbers depend mainly on the P. vivax strain used in the infections. Similar numbers of small forms are observed for up to 21 d. Importantly, 85% of the small forms observed were shown to be intracellular (thus ruling out possible axenic infection) 56 . In contrast, cultures infected with P. falciparum contained very few small forms after 2 weeks in culture, and those few observed were shown to be predominantly extracellular. Reactivation of potentially dormant, small P. vivax small forms has not been observed yet using this in vitro system, but it is an active area of investigation.
For HcV
If high-titer Gluc-expressing HCV is used to infect a highly permissive hepatocyte donor, infection generally results in a 10-fold increase in luminescent signal (RLU) over baseline at 5 d after infection (ideal stocks have TCID 50 per ml ~10 7 and are diluted 1:10 for infection, yielding a final multiplicity of infection (MOI) of ~5 for hepatocytes; MOI ~1 if 3T3-J2 cells are included in calculation). This signal decays over time, but it typically can be resolved over background for ~2 weeks (Fig. 5) . If the hepatocytes are transduced with the RFP-NLS-IPS reporter before infection, nuclear translocation of the RFP reporter (representing successful viral infection) is observed in ~1.5% of hepatocytes. It is sometimes possible to see small clusters of hepatocytes within certain islands exhibiting nuclear translocation, which may be a result of direct cell-cell transmission of HCV. In addition, infectious virions can be collected from the supernatant of infected MPCC cultures, typically maintaining a titer of 10 1 -10 2 TCID 50 per ml at 10-14 d after infection.
The HCV luciferase signal does decay over 2 weeks, yet we do find that both the luciferase readout and RFP-NLS-IPS reporter are sufficiently sensitive to perform testing of antiviral compounds. By using the luciferase reporter, treatment with a protease inhibitor (ITMN191), polymerase inhibitor (2′CMA) or immune activator (interferon; IFN) results in rapid decay of the signal to background levels, as early as 5-6 d after infection. By RFP-NLS-IPS reporter, untreated 'islands' contain about four hepatocytes exhibiting nuclear translocation of the reporter as early as 2 d after infection, whereas 2′CMA-treated islands rarely contain infected hepatocytes (~0.07 hepatocytes/island).
For HBV
If high-titer patient-derived virus (starting titer of ~10 8 -10 9 GE per ml before clot removal; yield after clot removal is about tenfold lower, and then diluted 1:10-1:20 in culture medium) is used to infect a highly permissive hepatocyte donor, HBV infection results in sustained production of HBsAg, robust transcription of viral RNAs and establishment of a cccDNA pool (Fig. 6) . As discussed more thoroughly in a recent publication 58 , inhibition of the hepatocyte interferon-inducible innate immune response, by treating cultures with a pan-JAK inhibitor (JAKi), results in even more robust infection, including sustained production of HBV E antigen (a clinical marker of active viral replication), and growth in the cccDNA pool over time. Upon JAKi treatment, ~20-25% of hepatocytes stain positive for HBV Core protein, which generally exhibits nuclear localization as expected, given its incorporation into the HBV cccDNA 'minichromosome' .
HBV-infected MPCCs respond to antiviral drug treatment in ways that match clinical outcomes, providing a useful platform for testing new antivirals. Upon pretreatment of MPCCs with either entecavir (a reverse transcriptase inhibitor) or IFN, HBV titers are markedly reduced, along with all other viral readouts including cccDNA. However, when drug treatment is started after an infection is established (e.g. at 7 d after infection), responses to the two drugs differ. IFN, a multifunctional innate immune stimulator that can generate cures in a small minority of prolonged HBV infections, effectively decreases the amount of viral transcription and the levels of cccDNA in infected cells. Entecavir, in contrast, is very effective at reducing the viral titer by preventing reverse transcription, but it does not affect forward transcription or cccDNA levels. This mimics the clinical scenario, in which entecavir prevents viral rebound but cannot cure chronically infected patients.
